Genmab A/S

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 16:20:00 15/06/2026 BST			5-day change	1st Jan Change
1,594.00 ^DKK	-1.54%		+0.66%	-21.36%

05:57am	Nordic Equities in North America: Ericsson Slides 1.4 Percent	FW
06-13	Genmab Announces Epcoritamab Monotherapy And Epcoritamab-Based Combination Regimens Demonstrate High Response Rates In Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma	CI

Nordea resumes coverage of Genmab with Buy rating and DKK 2,015 price target

Published on 05/12/2026 at 07:35 am BST

Finwire - Translated by Marketscreener - See original

GENMAB A/S

-1.54%

Nordea has resumed coverage of Genmab, assigning a Buy rating with a price target of DKK 2,015.

Latest news about Genmab A/S

05:57am	Nordic Equities in North America: Ericsson Slides 1.4 Percent	FW
06-13	Genmab Announces Epcoritamab Monotherapy And Epcoritamab-Based Combination Regimens Demonstrate High Response Rates In Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma	CI
06-11	Genmab Says Subgroup Data for Follicular Lymphoma Treatment Shows 'Sustained' Efficacy Benefits	MT
06-11	Genmab A/S Presents EPCORE FL-1 Subgroup Data Demonstrating Consistent Efficacy And Safety Results For Epcoritamab In Combination With Rituximab And Lenalidomide R2 Across Relapsed Or Refractory Follicular Lymphoma Patients	CI
06-10	Nordic stocks in North America - Autoliv rose 1.6 percent	FW
06-09	Nordic Equities in North America - AstraZeneca declines 1.8 percent	FW
06-08	Nordic stocks in North America - Ericsson fell 1.8 percent	FW
06-03	Nordic Equities in North America - Ericsson Gains 0.7 Percent	FW
06-02	U.S. Futures Slip, European Stocks Edge Up	DJ
06-01	U.S. Futures Edge Up, European Stocks Mixed	DJ
05-25	Nordic Equities in North America - Astra Zeneca Slips 0.9 Percent	FW
05-20	Nordic Equities in North America - Autoliv Gains 0.9 Percent	FW
05-18	Genmab Maintained at Buy as BofA Notes Upcoming Key Catalysts	MT
05-12	Nordea resumes coverage of Genmab with Buy rating and DKK 2,015 price target	FW
05-11	Deutsche Bank trims Genmab price target to DKK 2,250 (2,400), reiterates Buy	FW

Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.4%); - income from sales of products (10.7%); - other (5.9%): primarily income from partnership agreement. Net sales are distributed geographically as follows: Denmark (89.4%), the United States (4.9%) and Japan (5.7%).

Employees

3,088

Sector

Biotechnology & Medical Research

Calendar

08-06 - Earnings release - Q2 2026

More about the company